<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Han Y</submitter><funding>Natural Science Foundation of Guangdong Province</funding><funding>National Natural Science Foundation of China</funding><pagination>852775</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC8920042</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>9</volume><pubmed_abstract>Enhancement of protein synthesis from mRNA translation is one of the key steps supporting cardiomyocyte hypertrophy during cardiac remodeling. The methyltransferase-like5 (METTL5), which catalyzes m&lt;sup>6&lt;/sup>A modification of 18S rRNA at position A&lt;sub>1832&lt;/sub>, has been shown to regulate the efficiency of mRNA translation during the differentiation of ES cells and the growth of cancer cells. It remains unknown whether and how METTL5 regulates cardiac hypertrophy. In this study, we have generated a mouse model, METTL5-cKO, with cardiac-specific depletion of METTL5 &lt;i>in vivo&lt;/i>. Loss function of METTL5 promotes pressure overload-induced cardiomyocyte hypertrophy and adverse remodeling. The regulatory function of METTL5 in hypertrophic growth of cardiomyocytes was further confirmed wit</pubmed_abstract><journal>Frontiers in cardiovascular medicine</journal><pubmed_title>Loss of m&lt;sup>6&lt;/sup>A Methyltransferase METTL5 Promotes Cardiac Hypertrophy Through Epitranscriptomic Control of SUZ12 Expression.</pubmed_title><pmcid>PMC8920042</pmcid><funding_grant_id>81873463</funding_grant_id><funding_grant_id>81970429</funding_grant_id><funding_grant_id>2021A1515010433</funding_grant_id><funding_grant_id>2018A030313448</funding_grant_id><funding_grant_id>81900350</funding_grant_id><funding_grant_id>2019A1515011956</funding_grant_id><funding_grant_id>2019B151502003</funding_grant_id><pubmed_authors>Zhang D</pubmed_authors><pubmed_authors>Dong Y</pubmed_authors><pubmed_authors>Lin S</pubmed_authors><pubmed_authors>Du T</pubmed_authors><pubmed_authors>Liao X</pubmed_authors><pubmed_authors>Zhuang X</pubmed_authors><pubmed_authors>Han Y</pubmed_authors><pubmed_authors>Guo S</pubmed_authors><pubmed_authors>Wang L</pubmed_authors><pubmed_authors>Long T</pubmed_authors><pubmed_authors>Li S</pubmed_authors><pubmed_authors>Tan X</pubmed_authors><pubmed_authors>Lui KO</pubmed_authors><pubmed_authors>Dai G</pubmed_authors><pubmed_authors>Xu T</pubmed_authors><pubmed_authors>Huang ZP</pubmed_authors><pubmed_authors>Chen Y</pubmed_authors><pubmed_authors>Liu C</pubmed_authors></additional><is_claimable>false</is_claimable><name>Loss of m&lt;sup>6&lt;/sup>A Methyltransferase METTL5 Promotes Cardiac Hypertrophy Through Epitranscriptomic Control of SUZ12 Expression.</name><description>Enhancement of protein synthesis from mRNA translation is one of the key steps supporting cardiomyocyte hypertrophy during cardiac remodeling. The methyltransferase-like5 (METTL5), which catalyzes m&lt;sup>6&lt;/sup>A modification of 18S rRNA at position A&lt;sub>1832&lt;/sub>, has been shown to regulate the efficiency of mRNA translation during the differentiation of ES cells and the growth of cancer cells. It remains unknown whether and how METTL5 regulates cardiac hypertrophy. In this study, we have generated a mouse model, METTL5-cKO, with cardiac-specific depletion of METTL5 &lt;i>in vivo&lt;/i>. Loss function of METTL5 promotes pressure overload-induced cardiomyocyte hypertrophy and adverse remodeling. The regulatory function of METTL5 in hypertrophic growth of cardiomyocytes was further confirmed wit</description><dates><release>2022-01-01T00:00:00Z</release><publication>2022</publication><modification>2026-05-31T08:09:25.973Z</modification><creation>2024-11-14T20:17:33.713Z</creation></dates><accession>S-EPMC8920042</accession><cross_references><pubmed>35295259</pubmed><doi>10.3389/fcvm.2022.852775</doi></cross_references></HashMap>